We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » J&J Reports Steady Procrit Sales for First Quarter
J&J Reports Steady Procrit Sales for First Quarter
April 25, 2007
U.S. sales of Johnson & Johnson's (J&J) erythropoiesis-stimulating agent (ESA) Procrit remained steady during the fourth quarter of 2007 despite recent drug safety issues associated with the use of ESAs.